San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Vividion Therapeutics is raising $82,000,011.00 in a new round of investment. Sources indicate as part of senior management President, Fred Aslan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vividion Therapeutics

Vividion Therapeutics is expanding the therapeutic potential of small molecules to create transformative medicines. Our cutting-edge platform combines proteomics and pioneering chemistry to reveal druggable opportunities across the entire proteome, much of it previously considered undruggable. We are advancing a pipeline of programs across a range of unmet medical needs. To learn more about Vividion Therapeutics, visit http://www.vividion.com/

Contact:
Fred Aslan, President
858-345-4690
freda@vividion.com
https://www.linkedin.com/in/fred-aslan-7b2ba41/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved